Unknown

Dataset Information

Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.


ABSTRACT:

Purpose

Multimodality treatment of squamous cell carcinoma of the head and neck (SCCHN) often involves radiotherapy and cisplatin-based therapy. Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) pathway, of which ERCC1 is a rate-limiting element, are associated with cisplatin and possibly RT resistance. We have determined excision repair cross-complementing group 1 (ERCC1) expression in human papillomavirus (HPV)-negative SCCHN treated with surgery [± adjuvant radiotherapy/chemoradiation (CRT)].

Experimental design

We assessed ERCC1 protein expression in archival tumors using immunofluorescence staining and automatic quantitative analysis (AQUA) with three antibodies to ERCC1 (8F1, FL297, and HPA029773). Analysis with Classification and

SUBMITTER: Mehra R 

PROVIDER: S-EPMC4045641 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature